New sulfonated distamycin a derivatives with bFGF complexing activity
References (34)
- et al.
Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis
Microvasc Res
(1977) - et al.
Inhibitory effect of suramin on receptor binding and cytotoxic activity of tumor necrosis factor α
Int J Immunopharmacol
(1992) - et al.
An in vivo model for study of the angiogenic effects of basic fibroblast growth factor
Biochem Biophys Res Commun
(1987) - et al.
Acidic and basic fibroblast growth factors stimulate tyrosine kinase activity in vivo
J Biol Chem
(1988) Angiogenesis and oncogenesis
J Natl Cancer Inst
(1978)- et al.
Angiogenesis: a marker for neoplastic transformation of mammary capillary hyperplasia
Science
(1977) What is the evidence that tumors are angiogenesis dependent?
J Natl Cancer Inst
(1990)- et al.
Angiogenic factors
Science
(1987) - et al.
Suramin prevents neovascularisation and tumor growth through blocking of basic fibroblast growth factor activity
Br J Cancer
(1992) - et al.
Suramin: an anticancer drug with a unique mechanism of action
J Clin Oncol
(1989)
Treatment of hormonally refractory prostate cancer with suramin
Effect of suramin in patients with refractory nodular lymphomas requiring systemic therapy
Differential inhibition of various deoxyribonucleic and ribonucleic acid polymerases by suramin
EurJ Biochem
Inhibition of vacuolar H+ ATPases by fusidic acid and suramin
FEBS Lett
Differential effects of suramin on the coupling of receptors to individual species of pertussis-toxin sensitive guanine-nucleotide-binding proteins
Biochem J
Suramin inhibition of growth factor receptor binding and mitogenicity in ARK-2B cells
J Cell Physiol
Suramin binds to platelet-derived growth factor and inhibits its biological activity
J Cell Biochem
Cited by (52)
Arylamidonaphtalene sulfonate compounds as a novel class of heparanase inhibitors
2017, Bioorganic and Medicinal Chemistry LettersDNA minor groove binders: Back in the groove
2009, Cancer Treatment ReviewsCitation Excerpt :The next clinically relevant derivative of distamycin to enter development was the drug PNU-145156E, previously named FCE 26644. Though derived from the DNA binding distamycin backbone, initial experiments revealed that the primary method of action of this drug and similar agents was the binding of basic fibroblast growth factor, a pleiotropic cytokine important in angiogenesis.22 Despite apparent lack of cytotoxcity on its own, PNU-145156E showed combinatorial efficacy with other cytotoxic drugs23 and entered phase I trials.
Interaction between basic fibroblast growth factor and the anti-angiogenic drug PNU145156E
2006, Journal of Molecular StructureApplication of the four-component Ugi condensation for the preparation of sulfated glycoconjugate libraries
2004, Bioorganic and Medicinal Chemistry LettersNature of interaction between basic fibroblast growth factor and the antiangiogenic drug 7,7-(carbonyl-bis[imino-N-methyl-4,2-pyrrolecarbonylimino [N-methyl-4,2-pyrrole]-carbonylimino])-bis-(1,3-naphtalene disulfonate). II. Removal of polar interactions affects protein folding
2002, Biophysical JournalCitation Excerpt :Since the demonstration of the role of angiogenesis in cancer, the search for angiogenesis inhibitors has become the focus of several research groups (Herblin et al., 1994; Auerbach and Auerbach, 1994). In the last few years, naphthalene sulfonic distamycin-A derivatives were shown to inhibit the binding of human recombinant bFGF to its receptors, to block in vivo bFGF-induced vascularization and to stop neovascularization in chorioallantoic membrane (Ciomei et al., 1993). Suramin is one such polysulfonated naphthylurea that was examined as a potential anticancer drug (La Rocca et al., 1990; Kohler et al., 1992; Braddock et al., 1994; Manetti et al., 1998, 2000).